Ptc Therapeutics PTCT Estimates

NASDAQ PTCT
$69.92 -1.48 (-2.07%)
As of: Sep 4, 2026 · 11:47 AM EDT
Analyst Estimates

Ptc Therapeutics, Inc. Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 297.91 M

Analysts expect Ptc Therapeutics, Inc. to report revenue of 297.91 M for Q3 26, against a range of 285.24 M to 310.58 M. The most recent reported quarter, Q2 26, came in at 360.52 M, a 14.8% beat against the 314.18 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 196.79 M213.17 M1.18 B178.88 M211.01 M164.68 M272.55 M360.52 M--------
High Estimate 190.14 M238.65 M193.45 M175.92 M170.89 M317.30 M228.13 M344.27 M310.58 M357.32 M291.90 M324.82 M357.66 M398.96 M480.15 M378.65 M
Low Estimate 172.26 M212.52 M165.55 M148.91 M153.09 M269.18 M192.04 M284.08 M285.24 M314.95 M269.49 M302.46 M295.81 M344.17 M416.97 M321.94 M
Consensus Estimate 181.20 M225.59 M179.50 M162.42 M161.99 M293.24 M210.09 M314.18 M297.91 M336.14 M280.69 M313.64 M326.74 M371.56 M448.56 M350.30 M
Analyst Estimates

Ptc Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus 0.40

Analysts expect Ptc Therapeutics, Inc. to report earnings per share of 0.40 for Q3 26, against a range of 0.38 to 0.42. The most recent reported quarter, Q2 26, came in at 0.92, a 268.0% beat against the 0.25 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -1.39-0.8510.04-0.830.20-1.67-0.030.92--------
High Estimate -1.31-0.46-0.98-0.90-1.100.11-0.420.260.420.330.320.550.950.621.910.30
Low Estimate -1.59-0.54-1.16-1.06-1.300.09-0.460.240.380.270.280.450.870.581.710.28
Consensus Estimate -1.45-0.50-1.07-0.98-1.200.10-0.440.250.400.300.300.500.910.601.810.29